Quarterly Earnings Release dated May 09, 2026
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong Q4 FY26 results with revenue of ₹2,034 million (up 22% YoY) and PAT of ₹453 million (up 69% YoY). Full year FY26 revenue stood at ₹7,458 million with 17% growth and PAT of ₹1,736 million with 30% growth. EBITDA margin improved significantly to 31% in Q4 FY26 from 27% in Q4 FY25, while maintaining zero-debt status. All four segments showed healthy growth - Human Nutrition grew 24% YoY (₹1,281 million), Animal Nutrition rose 19% (₹250 million), Bio-Processing increased 17% (₹324 million), and Specialized Manufacturing grew 17% (₹180 million). Domestic sales surged 51% YoY to ₹1,061 million, now representing 52% of total revenue versus 42% a year ago. The company launched its own nutraceutical brand 'Wellfa' in India and outlined plans for continued expansion in probiotics, B2C business, and inorganic growth through strategic acquisitions.
The strong margin expansion and profit growth demonstrate operational efficiency improvements and pricing power, which should be positive for the stock. The shift toward domestic sales and B2C expansion reduces geographical concentration risk and could drive valuation re-rating.